zepbound review

Zepbound is an FDA-approved injectable prescription medicine developed by Eli Lilly and Company for chronic weight management in adults with obesity or overweight with at least one weight-related comorbid condition. It is the first and only FDA-approved obesity treatment that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound contains tirzepatide, which mimics a hormone that helps reduce food cravings and is used in Eli Lillys diabetes drug Mounjaro. The drug should be used with a reduced-calorie diet and increased physical activity. However, it is important to note that Zepbound should not be used if an individual has had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound, and it may cause gastrointestinal adverse reactions, sometimes severe. Zepbound is given in six injectable doses and is expected to be available at a list price of $1,059. It is essential for individuals to consult a healthcare professional for more information and to determine if Zepbound is suitable for their specific medical condition.